Cervical, anal and oral hpv in an adolescent inner-city health clinic providing free vaccinations

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Schlecht, Nicolas F ^a   Burk, Robert D ^a   Nucci Sack, Anne ^b   Shankar, Viswanathan ^a   Peake, Ken ^b   Lorde Rollins, Elizabeth ^b   Porter, Richard ^b   Linares, Lourdes Oriana ^b   Rojas, Mary ^c   Strickler, Howard D ^a   Diaz, Angela ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANAL HUMAN PAPILLOMAVIRUS INFECTION; ANUS DISEASE; ARTICLE; CAUCASIAN; CERVICAL HUMAN PAPILLOMAVIRUS INFECTION; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HISPANIC; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION RISK; MAJOR CLINICAL STUDY; MOUTH INFECTION; NONHUMAN; ORAL HUMAN PAPILLOMAVIRUS INFECTION; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; SEXUAL INTERCOURSE; TREATMENT RESPONSE; UNITED STATES; URBAN AREA; UTERINE CERVICITIS; VACCINATION; VIRUS DETECTION; ANAL CANAL; CROSS-SECTIONAL STUDY; GENOTYPE; MOUTH; QUESTIONNAIRE; RISK; SEXUAL BEHAVIOR; UTERINE CERVIX; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

ADOLESCENT; ANAL CANAL; CERVIX UTERI; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HUMANS; MOUTH; NEW YORK CITY; ODDS RATIO; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; QUESTIONNAIRES; SEXUAL BEHAVIOR; YOUNG ADULT;

EID: 84862063512     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037419     Document Type: Article

References (23)

1. Haupt RM, Wheeler CM, Brown DR, Garland SM, Ferris DG, et al. (2011) Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int J Cancer 129: 2632-2642.
2. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, et al. (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356: 1928-1943.
3. Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2009) Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human vaccines 5: 696-704.
4. Villa L, Ault K, Giuliano A, Costa R, Petta C, et al. (2006) Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 24: 5571-5583.
5. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, et al. (2011) HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. The New England journal of medicine 365: 1576-1585.
6. Kreimer AR, Gonzalez P, Katki HA, Porras C, Schiffman M, et al. (2011) Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 12: 862-870.
7. Castle PE, Schiffman M, Gravitt PE, Kendall H, Fishman S, et al. (2002) Comparisons of HPV DNA detection by MY09/11 PCR methods. Journal of medical virology 68: 417-423.
8. Bottalico D, Chen Z, Dunne A, Ostoloza J, McKinney S, et al. (2011) The oral cavity contains abundant known and novel human papillomaviruses from the Betapapillomavirus and Gammapapillomavirus genera. The Journal of infectious diseases 204: 787-792.
9. Qu W, Jiang G, Cruz Y, Chang C, Ho G, et al. (1997) PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol 35: 1304-1310.
10. Kovacic MB, Castle PE, Herrero R, Schiffman M, Sherman ME, et al. (2006) Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Research 66: 10112-10119.
11. Xue X, Gange SJ, Zhong Y, Burk RD, Minkoff H, et al. (2010) Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev 19: 159-169.
12. Greenland S, Robins JM, (1986) Identifiability, exchangeability, and epidemiological confounding. International journal of epidemiology 15: 413-419.
13. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527.
14. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, et al. (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366: 991-998.
15. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, et al. (2009) A review of human carcinogens? Part B: biological agents. The Lancet Oncology 10: 321-322.
16. Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, et al. (2011) HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29: 2011-2014.
17. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, et al. (2012) Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. The Lancet Oncology 13: 100-110.
18. FUTURE II, (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356: 1915-1927.
19. Paavonen J, (2008) Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials. Current medical research and opinion 24: 1623-1634.
20. Mao C, Koutsky L, Ault K, Wheeler C, Brown D, et al. (2006) Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial. Obstet Gynecol 107: 18-27.
21. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, et al. (2011) Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute 103: 1444-1451.
22. Katki H, Kreimer A, Gonzalez P, Porras C, Schiffman M, et al. (2011) HPV vaccine efficacy against both cervical and anal HPV16/18 infection. Abstract No. O-18.07. International Papillomavirus Meeting. Berlin, Germany.
23. Kreimer AR, Gonzalez P, Katki HA, Porras C, Schiffman M, et al. (2011) Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. The Lancet Oncology 12: 862-870.